Beta Amyloid / Amyloid / Neurodegenerative Diseases · Observational Study

Beta Amyloid PET/CT in Various Aβ-Related Disease

ClinicalTrials.gov · September 8, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a recruiting observational study registration evaluating 18F-92/AV45 and 11C-PIB PET/CT imaging in patients with amyloid-related and tau-related neurodegenerative disease. No results have been posted; the registry record describes the planned protocol only, and does not support any conclusion about diagnostic accuracy, clinical utility, or patient outcomes.

What was studied

Observational. Amyloid, Beta-Amyloid, Neurodegenerative Diseases; age from 18 Years; to 80 Years; accepts healthy volunteers. Intervention: Single Group Assignment. n = 500. 4 sites: China.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a recruiting observational registry study with no reported results; it represents planned diagnostic evaluation in a disease area, not yet generating evidence on clinical utility or accuracy.

Study design

As stated by the source record.

MethodsCohort model. Prospective time perspective. Primary outcome measure: Standardized uptake value (SUV) (assessed at 30 days)

DesignObservational

PopulationAmyloid, Beta-Amyloid, Neurodegenerative Diseases; age from 18 Years; to 80 Years; accepts healthy volunteers

Sample size500

InterventionSingle Group Assignment

Setting4 sites: China

Reported figures

Quoted from the source exactly as published.

Planned enrollment500

Primary outcome measureStandardized uptake value (SUV)

Follow-up timeframe30 days

Caveats

Registry record only; no results posted. This describes a planned study, not completed research.
No comparator or reference standard disclosed in registry summary.
Diagnostic accuracy, sensitivity, specificity, and clinical utility not yet reported.
Sample size is estimated; final enrolled cohort unknown.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

limited

Observational design without control or comparator arm described.

Directness

moderate

Directly measures SUV by PET/CT; clinical utility or diagnostic accuracy not yet reported.

Consistency

insufficient

Single study; no baseline comparison data provided in registry record.

Risk of bias

insufficient

Registry record does not describe blinding, patient selection, or reference standard.

Sample adequacy

moderate

Estimated 500 participants planned; enrollment ongoing, final sample unknown.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT06725706). This is a study registration, not published results. Lead sponsor: Tianjin Medical University. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 500 participants (ESTIMATED). Conditions: Amyloid, Beta-Amyloid, Neurodegenerative Diseases. Interventions: DIAGNOSTIC_TEST: 18F-92/AV45, 11C-PIB. Primary outcome measures: Standardized uptake value (SUV) , 30 days. Brief summary: To evaluate the potential usefulness of 18F-92/AV45, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Beta AmyloidAmyloidTianjin Medical UniversityNeurodegenerative DiseasesNCT0672570618F-92/AV45, 11C-PIB